Overview

Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis

Status:
Completed

Trial end date:
2017-08-01

Target enrollment:

Participant gender:

Summary

The mail goal of this study is to establish superiority in efficacy of Acellbia® applied in a dose of 600 mg (Day 1 and Day 15) in combination with methotrexate in patients with active RA seropositive previously untreated with biological therapy, compared to standard therapy with methotrexate.

Phase:

Phase 3

Details

Lead Sponsor:

Biocad

Treatments:

Antibodies, Monoclonal
Methotrexate
Rituximab